Fig. 3: Assessment of KRAS mutations in plasma samples. | Cell Death & Disease

Fig. 3: Assessment of KRAS mutations in plasma samples.

From: Circulating tumor DNA in patients with colorectal adenomas: assessment of detectability and genetic heterogeneity

Fig. 3

Bar charts show merged data from two runs for each patient sample. The number of WT (green bars) and mutant (blue bars) copies detected are shown on left y-axis. The total number of droplets analyzed (gray dots) are indicated on right y-axis. a KRAS-c.35; b KRAS-c.34; c KRAS-c.38. The “+ve con” indicates positive control from 10 ng of genomic DNA isolated from SW480 (c.35G>T/p.G12V) CRC cell line, A549 (c.34G>A/p.G12S) lung cancer cell line, and HCT116 (c.38G>A/p.G13D) CRC cell line. The “–ve con” indicates negative control from 10 ng of hgDNA. NTC no template control

Back to article page